Skip to main content
. 2017 Jun 22;7(3):31. doi: 10.3390/metabo7030031

Figure 1.

Figure 1

Echocardiographic analysis of the effects of the tyrosine kinase inhibitors erlotinib and sunitinib on cardiac function. FVB/N mice were treated with sunitinib (40 mg/kg), erlotinib (50 mg/kg), or vehicle daily for 2 weeks and serially echoed at baseline and after 2 weeks. (A) Fractional shortening % and (B) LV Volume (in Systole) at baseline and 14 days of erlotinib (blue), sunitinib (orange), or vehicle control (gray) treatment in vivo. A Student’s t-test was used to determine significance between groups (defined as p < 0.05). Values are expressed as mean values ± SE (N = 10/group).